Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Inclusion * Allogeneic HCT with marrow or growth-factor mobilized blood cells from an HLA-A, B, C, DRB1, and HLA-DQB1-allele matched or single-allele or antigen mismatched related or unrelated donor * Use of myeloablative pre-transplant conditioning regimen with \> 800 cGy total body irradiation and cyclophosphamide, or high-dose busulfan and cyclophosphamide * Use of methotrexate and tacrolimus for prevention of GVHD after allogeneic HCT * Informed consent document signed Exclusion * Cord blood transplant recipients * Use of T cell depletion or rabbit antithymocyte globulin to prevent acute GVHD * Treatment with rabbit antithymocyte globulin or alemtuzumab within 3 months before the date of HCT * Participation in another therapeutic trial where the primary endpoint is related to acute GVHD * Hospitalization at the beginning of the pre-transplant conditioning regimen because of pre-existing medical complications * Glucocorticoid treatment at prednisone-equivalent doses \> 0.2 mg/kg/day * Known intolerance to BDP * Anticipated inability to tolerate oral administration of study drug tablets for any reason during the first two weeks after HCT * Body weight \< 35 kg (lower-dose formulations are not available for subjects with lower body weight) * Pregnancy or breast feeding * Women of child-bearing potential who are unwilling to use a reliable method of contraception * Incarceration